ABC 1183

Drug Profile

ABC 1183

Alternative Names: ABC1183

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apogee Biotechnology Corporation
  • Class Anti-inflammatories; Antineoplastics; Thiazoles
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Glycogen synthase kinase 3 alpha inhibitors; Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 15 Nov 2016 Preclinical trials in Cancer in USA (PO)
  • 15 Nov 2016 Preclinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top